Medtronic Cardiac Ablation Registry platform

  • Research type

    Research Study

  • Full title

    Medtronic Cardiac Ablation (MCA) Registry, base CIP

  • IRAS ID

    294290

  • Contact name

    Tarvinder Dhanjal

  • Contact email

    tarv.dhanjal@uhcw.nhs.uk

  • Sponsor organisation

    Medtronic

  • Clinicaltrials.gov Identifier

    NCT04735016

  • Duration of Study in the UK

    9 years, 8 months, 31 days

  • Research summary

    The Medtronic Cardiac Ablation Registry platform will look at the performance (i.e. how well) and safety of different Medtronic Ablation Systems.

    Cardiac Ablation therapy is used to treat irregular heart rhythms. Cardiac ablation therapy is established as an acceptable therapy to treat patients with AF when drug therapy has failed. Current ablation systems ablate heart tissue by either heating or freezing the tissue.
    The registry is not an experimental study. For this registry, we will only be collecting data, assessed in a "real-life" environment, where patients are managed as they would be in routine care, using devices already approved. The duration of data collection will be determined by the product received by the patient. The registry design allows for new, already approved Medtronic Ablation products, to be added over time.

    The DiamondTemp Addendum:
    The first approved product added to the Medtronic Cardiac Ablation Registry is called DiamondTemp. The aim of this study is to look at the number of safety events and how well controlled patients heart rhythms are in the 12months following treatment with the study device.

  • REC name

    North East - York Research Ethics Committee

  • REC reference

    21/NE/0092

  • Date of REC Opinion

    6 Aug 2021

  • REC opinion

    Further Information Favourable Opinion